Indeed, dose reductions or interruptions, increased metabolism or reduced absorption, hypoperfusion, and a poor penetration of the blood–brain barrier may favor the development of pharmacological resistance to anti-EGFR agents in EGFR-addicted NSCLC patients [5,19]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.